118 related articles for article (PubMed ID: 3653210)
21. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer.
Holtkamp W; Nagel GA; Wander HE; Rauschecker HF; von Heyden D
Int J Cancer; 1984 Sep; 34(3):323-8. PubMed ID: 6480153
[TBL] [Abstract][Full Text] [Related]
22. [Blood prolactin level of breast and endometrial cancer patients during surgical intervention].
Pozdniakov VV; Bobrov IuF; Gamaiunova VB; Evtiukhin AI; Frid IA
Vopr Onkol; 1984; 30(2):9-14. PubMed ID: 6702135
[TBL] [Abstract][Full Text] [Related]
23. A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia.
Lissoni P; Mainini E; Mazzi C; Cattaneo G; Barni S
J Endocrinol Invest; 1990 Feb; 13(2):85-9. PubMed ID: 2329263
[TBL] [Abstract][Full Text] [Related]
24. Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients.
Lagendijk M; van Maaren MC; Saadatmand S; Strobbe LJA; Poortmans PMP; Koppert LB; Tilanus-Linthorst MMA; Siesling S
Int J Cancer; 2018 Jan; 142(1):165-175. PubMed ID: 28884470
[TBL] [Abstract][Full Text] [Related]
25. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas.
Arafah BM; Nekl KE; Gold RS; Selman WR
J Clin Endocrinol Metab; 1995 Dec; 80(12):3507-12. PubMed ID: 8530591
[TBL] [Abstract][Full Text] [Related]
26. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia.
Lissoni P; Mandalà M; Rovelli F; Casu M; Rocco F; Tancini G; Scardino E
Eur Urol; 2000 May; 37(5):569-72. PubMed ID: 10765095
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
Frontini L; Lissoni P; Vaghi M; Perego MS; Pescia S; Ardizzoia A; Gardani G
Anticancer Res; 2004; 24(6):4223-6. PubMed ID: 15736476
[TBL] [Abstract][Full Text] [Related]
28. Serum prolactin levels in women with breast cancer and their relationship to survival.
Wang DY; Hampson S; Kwa HG; Moore JW; Bulbrook RD; Fentiman IS; Hayward JL; King RJ; Millis RR; Rubens RD
Eur J Cancer Clin Oncol; 1986 Apr; 22(4):487-92. PubMed ID: 3732352
[TBL] [Abstract][Full Text] [Related]
29. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Viganò P; Strada G
Int J Biol Markers; 2005; 20(2):123-5. PubMed ID: 16011043
[TBL] [Abstract][Full Text] [Related]
30. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Pannuti F; Martoni A; Farabegoli G; Piana E
Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487
[TBL] [Abstract][Full Text] [Related]
31. Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody.
Hattori N; Ikekubo K; Ishihara T; Moridera K; Hino M; Kurahachi H
Eur J Endocrinol; 1994 May; 130(5):438-45. PubMed ID: 8180669
[TBL] [Abstract][Full Text] [Related]
32. Lack of association between hyperprolactinemia and colon carcinoma.
Carlson HE; Zarrabi MH; Lyubsky SL
Cancer Invest; 2000; 18(2):130-4. PubMed ID: 10705875
[TBL] [Abstract][Full Text] [Related]
33. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
[TBL] [Abstract][Full Text] [Related]
34. Relationship between PRL levels and steroid receptors in breast cancer.
Marugo M; Fazzuoli L; Bernasconi D; Berta S; Giordano G
Anticancer Res; 1988; 8(4):819-23. PubMed ID: 3178171
[TBL] [Abstract][Full Text] [Related]
35. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
36. Antipsychotic treatment, prolactin, and breast tumorigenesis.
De Hert M; Vancampfort D; Stubbs B; Sabbe T; Wildiers H; Detraux J
Psychiatr Danub; 2016 Sep; 28(3):243-254. PubMed ID: 27658833
[TBL] [Abstract][Full Text] [Related]
37. Serum prolactin levels and their relationship to survival in women with operable breast cancer.
Wang DY; Stepniewska KA; Allen DS; Fentiman IS; Bulbrook RD; Kwa HG; De Stavola BL; Reed MJ
J Clin Epidemiol; 1995 Jul; 48(7):959-68. PubMed ID: 7782804
[TBL] [Abstract][Full Text] [Related]
38. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors.
Schlechte JA; Sherman BM; Chapler FK; VanGilder J
J Clin Endocrinol Metab; 1986 Jun; 62(6):1296-301. PubMed ID: 3084539
[TBL] [Abstract][Full Text] [Related]
39. Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
J Biol Regul Homeost Agents; 2004; 18(3-4):291-4. PubMed ID: 15786695
[TBL] [Abstract][Full Text] [Related]
40. Plasma prolactin levels in patients with breast cancer.
Rose DP; Pruitt BT
Cancer; 1981 Dec; 48(12):2687-91. PubMed ID: 7306924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
